{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Number of participants that achieved Complete remission (CR) 9 months post auto transplant.\n\nComplete remission (CR) (all of the following):\n\n1. Negative immunofixation in serum and urine.\n2. \\< 5% plasma cells in the bone marrow.\n3. Disappearance of any soft tissue plasmacytomas.","groups":[{"description":"Beginning 60 days to 180 (+/- 14) days post ASCT, patients with relapsed multiple myeloma prior to transplant, or undergone previous ASCT, followed by relapse and at least a partial response to salvage therapy will receive maintenance therapy with daratumumab/hyaluronidase-fihj and pomalidomide.\n\nDaratumumab 1800 mg/hyaluronidase-fihj 30,000 units will be given SC weekly for weeks 1-8, followed by every 2 weeks for weeks 9-24, and then every month for weeks 25 until progression.\n\nPomalidomide will be given at 2 mg PO daily from day 1-21 in the 28-day cycle for up to 4 weeks.","id":"OG000","title":"Maintenance Therapy With Daratumumab/Hyaluronidase-fihj/Pomalidomide Post ASCT in MM Patients."}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Within 9 months post salvage auto transplant","title":"Number of Participants With Complete Remission","type":"PRIMARY","unitOfMeasure":"Participants"}